Association of eNOS Glu298Asp gene polymorphism with circadian blood pressure rhythm

被引:2
|
作者
Ormezzano, O.
Amar, J.
Vehier, C. Mounier
Cambien, F.
Poirier, O.
Chamontin, B.
Francois, P.
Mallion, J-M
Baguet, J-P
机构
[1] CHU Michallon, Serv Cardiol & Hypertens Arterielle, Grenoble, France
[2] CHU Purpan, Serv Med Interne & Hypertens Arterielle, Toulouse, France
[3] CHU Lille, Serv Cardiol, F-59037 Lille, France
[4] Univ Paris 06, INSERM, U525, Paris, France
[5] CHU Michallon, Dept Veille Sanit, Grenoble, France
关键词
D O I
10.1038/sj.jhh.1002169
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Hypertensive patients with altered circadian blood pressure (BP) profile experience greater repercussion of hypertension on target organs and a higher risk of cardiovascular events, compared with those with physiological variations in BP. It has been demonstrated in animal models, that circadian variations in BP depend on several regulatory systems, in particular the nitric oxide-cGMP(1) pathway. eNOS298 Glu/Asp polymorphism is a functional variant and may alter the amount of NO generated or eNOS activity. 2 The objective of the present study was to find out whether eNOS298 gene polymorphism affects circadian BP regulation in 110 healthy subjects and 155 never-treated hypertensive patients recruited at Hypertension Units in Grenoble, Toulouse and Lille (France).
引用
收藏
页码:501 / 503
页数:3
相关论文
共 50 条
  • [1] Association of eNOS Glu298Asp gene polymorphism with circadian blood pressure rhythm
    O Ormezzano
    J Amar
    C Mounier Vehier
    F Cambien
    O Poirier
    B Chamontin
    P François
    J-M Mallion
    J-P Baguet
    [J]. Journal of Human Hypertension, 2007, 21 : 501 - 503
  • [2] Association of ENOS GLU298ASP gene polymorphism with circadian blood pressure rhythm.
    Ormezzano, Olivier
    Amar, Jacques
    Mounier-Vehier, Claire
    Cambien, Francois
    Poirier, Odette
    Chamontin, Bernard
    Francois, Patrice
    Mallion, Jean-Michel
    Baguet, Jean-Philippe
    [J]. JOURNAL OF HYPERTENSION, 2006, 24 : 281 - 281
  • [3] Association of eNOS gene polymorphism (Glu298Asp) with psoriasis
    Senturk, Nilgun
    Kara, Nurten
    Aydin, Fatma
    Gunes, Sezgin
    Yuksel, Esra Pancar
    Bagci, Hasan
    Turanli, Ahmet Yasar
    [J]. JOURNAL OF DERMATOLOGICAL SCIENCE, 2006, 44 (01) : 52 - 55
  • [4] Association of eNOS Glu298Asp gene polymorphism with ischemic stroke in Turkish patients
    Guldiken, B.
    Sipahi, T.
    Guldiken, S.
    Ustundag, S.
    Turgut, N.
    Budak, M.
    Ozkan, H.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 66 - 66
  • [5] Association of eNOS Glu298Asp gene polymorphism with essential hypertension in Asian Indians
    Srivastava, Kamna
    Narang, Rajiv
    Sreenivas, V.
    Das, Sabri
    Das, Nibhriti
    [J]. CLINICA CHIMICA ACTA, 2008, 387 (1-2) : 80 - 83
  • [6] Glu298Asp eNOS polymorphism is not associated with SLE
    Mucenic, T.
    Brenol, J. C. T.
    Bredemeier, M.
    dos Santos, B. Paiva
    Chies, J. A. B.
    Monticielo, O. A.
    Xavier, R. M.
    [J]. LUPUS, 2009, 18 (05) : 448 - 451
  • [7] The Relationship between eNOS Glu298Asp Polymorphism and the Changes of Blood Pressure and Induced by Metoprolol
    Liu, L. W.
    Han, L. L.
    Chen, G. L.
    Liu, H.
    Liu, Y. Q.
    Li, Y. S.
    [J]. CARDIOLOGY, 2010, 117 : 124 - 124
  • [8] eNOS Glu298Asp gene polymorphism in the cases of idiopathic thrombocytopenic purpura
    Arslan, F.
    Akarsu, S.
    Kara, M.
    Ustundag, B.
    Yuce, H.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 867 - 867
  • [9] Glu298Asp polymorphism of the eNOS gene is associated with coronary collateral development
    Gulec, Sadi
    Karabulut, Halil
    Ozdemir, Aydan Ongun
    Ozdol, Cagdas
    Turhan, Sibel
    Altin, Timucin
    Tutar, Eralp
    Genc, Yasemin
    Erol, Cetin
    [J]. ATHEROSCLEROSIS, 2008, 198 (02) : 354 - 359
  • [10] The functional consequence of the GLU298ASP polymorphism of the eNOS gene in humans.
    Lang, CC
    Chan, S
    Godfrey, V
    Butler, R
    Cassidy, AJ
    Fardon, T
    Choy, A
    Struthers, AD
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P65 - P65